Preclinical News and Research

RSS

Temple University Hospital to test multilayer stent in patients suffering from aortic aneurysm

Temple University Hospital (TUH) could be among the first U.S.-based hospitals to test a new device known as a multilayer stent in patients suffering from aortic aneurysm, a condition characterized by the formation of a potentially life-threatening bulge in the aorta.

28 Jan 2014

FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections

FOB Synthesis, Inc. has entered into a research and development option and license agreement with AstraZeneca for the development of a novel antibiotic to treat drug-resistant bacterial infections.

28 Jan 2014

Scientists start clinical trial of EDP-788 oral antibiotic to treat MRSA infections

Scientists have begun the first human clinical trial of EDP-788, an investigational oral antibiotic intended to treat methicillin-resistant Staphylococcus aureus (MRSA) infections.

27 Jan 2014

Study explores potential of antibody-drug conjugates and challenges in manufacturing them

After years of research, development and testing, a new class of drugs is emerging on the market with two frontrunners acting as harbingers of what's to come. The cover story in Chemical & Engineering News, ACS' weekly newsmagazine, explores the potential of these antibody-drug conjugates (ADCs) and the challenges in developing and manufacturing them.

27 Jan 2014

NIBIO signs collaboration agreement for clinical development of new mucosal TB vaccines

Japan's National Institute of Biomedical Innovation ("NIBIO"), Aeras and Create Vaccine Company, Ltd ("CREATE") announce today that they signed a collaboration agreement on December 26, 2013, on the preclinical and clinical development of new mucosal tuberculosis (TB) vaccines based on NIBIO's human parainfluenza type-2 (rhPIV2) vector technology.

27 Jan 2014

Most high-risk CV devices approved without clinical data

Many cardiac implantable electronic device models currently in use were approved via a Food and Drug Administration review process in which the models were assumed safe and effective based on approval of prior versions of the device, according to a study in the January 22/29 issue of JAMA.

From Medtronic 27 Jan 2014

First patient enrolled pilot clinical trial of NovoTTF Therapy plus gemcitabine for pancreatic adenocarcinoma

Novocure announced today that the first patient has enrolled in the EF-20 Study, an open label, pilot clinical trial of NovoTTF Therapy plus gemcitabine as first-line therapy for patients with locally advanced and metastatic pancreatic adenocarcinoma.

25 Jan 2014

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Inovio Pharmaceuticals, Inc. today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 (IL-33), that in combination with optimized DNA vaccines delivered by electroporation increased the potency and efficacy of the therapeutic response to the DNA vaccines in a preclinical study.

23 Jan 2014

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Starpharma today announced that it has received the necessary approvals to commence a phase 1 human clinical trial for its dendrimer-enhanced docetaxel (Taxotere®) chemotherapeutic product, referred to as DEP™-Docetaxel.

23 Jan 2014

Jackson Laboratory collaborates with Seoul National University to develop new mouse models, tumor repository

The Jackson Laboratory, in collaboration with Seoul National University, will receive a five-year, $7.5 million grant from the South Korean government for a large-scale cancer genomics project employing the latest sequencing technology and special JAX mouse models that can host human tumors.

22 Jan 2014

Study: CIEDs used by physicians today were approved as supplements to premarket approved models

The Food and Drug Administration (FDA) ensures that high-risk medical devices, such as implantable cardioverter-defibrillators and pacemakers, are safe and effective through its premarket approval (PMA) pathway, during which manufacturers must collect preclinical and clinical data before the device is approved.

From Medtronic 22 Jan 2014

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9).

21 Jan 2014

Researchers identify molecular mechanism by which cocaine alters brain's reward circuits, causes addiction

Researchers from the Icahn School of Medicine at Mount Sinai have identified a new molecular mechanism by which cocaine alters the brain's reward circuits and causes addiction.

21 Jan 2014

RBCC's partner Nano3D Biosciences develops new 3D bioprinting system

Rainbow Coral Corp. is well-positioned to capitalize on the revolution in medicine being spurred on by 3D printing technology thanks to the innovative BiO Assay, a new 3D bioprinting system developed by RBCC's joint venture partner, Nano3D Biosciences (n3D).

20 Jan 2014

Research uncovers new mechanism in brain cells that may help keep deadly neurological diseases in check

New research from David Westaway, PhD, of the University of Alberta and Jiri Safar, MD, Case Western Reserve University School of Medicine has uncovered a quality control mechanism in brain cells that may help keep deadly neurological diseases in check for months or years.

17 Jan 2014

Research findings may offer new way to treat prion diseases

New research from David Westaway, PhD, of the University of Alberta and Jiri Safar, PhD, Case Western Reserve University School of Medicine has uncovered a quality control mechanism in brain cells that may help keep deadly neurological diseases in check for months or years.

16 Jan 2014

FDA-regulated study investigates use of child's stem cells for acquired sensorineural hearing loss

Cord Blood Registry, the world's largest and most experienced newborn stem cell company, announces the start of a U.S. Food and Drug-regulated study being conducted at Florida Hospital for Children in Orlando to investigate the use of a child's stem cells from their own stored umbilical cord blood as a treatment for acquired sensorineural hearing loss.

16 Jan 2014

New discovery has potential to transform heart attack treatments

An Australian discovery has the potential to transform the treatment of a heart attack, after a new approach boosted heart function and reduced heart scarring in preclinical studies.

16 Jan 2014

MRI method to map creatine in heart may help detect disorders earlier than traditional methods

A new MRI method to map creatine at higher resolutions in the heart may help clinicians and scientists find abnormalities and disorders earlier than traditional diagnostic methods, researchers at the Perelman School of Medicine at the University of Pennsylvania suggest in a new study published online today in Nature Medicine.

13 Jan 2014

Texas researcher receives U.S. patent for new class of compounds that protect against TBI

A researcher in the School of Medicine at The University of Texas Health Science Center at San Antonio received a U.S. patent Dec. 31 for his discovery that a class of compounds is protective against traumatic brain injury.

13 Jan 2014

Preclinical News and Research

Temple University Hospital to test multilayer stent in patients suffering from aortic aneurysm

FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections

Scientists start clinical trial of EDP-788 oral antibiotic to treat MRSA infections

Study explores potential of antibody-drug conjugates and challenges in manufacturing them

NIBIO signs collaboration agreement for clinical development of new mucosal TB vaccines

Most high-risk CV devices approved without clinical data

First patient enrolled pilot clinical trial of NovoTTF Therapy plus gemcitabine for pancreatic adenocarcinoma

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Jackson Laboratory collaborates with Seoul National University to develop new mouse models, tumor repository

Study: CIEDs used by physicians today were approved as supplements to premarket approved models

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Researchers identify molecular mechanism by which cocaine alters brain's reward circuits, causes addiction

RBCC's partner Nano3D Biosciences develops new 3D bioprinting system

Research uncovers new mechanism in brain cells that may help keep deadly neurological diseases in check

Research findings may offer new way to treat prion diseases

FDA-regulated study investigates use of child's stem cells for acquired sensorineural hearing loss

New discovery has potential to transform heart attack treatments

MRI method to map creatine in heart may help detect disorders earlier than traditional methods

Texas researcher receives U.S. patent for new class of compounds that protect against TBI

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics